PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

Deerfield Management

New York, NYDEERFIELD-MANAGEMENT
0
Truth Cards
0
Partners Rated
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

Healthcare investment firm with $15B+ in assets spanning venture, growth, and public healthcare companies.

Classification
Slugdeerfield-management
HQNew York, NY
Stage FocusExclusively healthcare-focused from early stage to growth…
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

Deerfield is the definition of a healthcare heavyweight — one of the largest dedicated healthcare funds globally with serious operational chops. Flynn has built something genuinely differentiated: they don't just write checks, they roll up their sleeves with in-house R&D (3DC), their own innovation campus (Cure), and deep academic partnerships. The good news? They're genuinely helpful post-investment and know how to navigate complex healthcare deals. The elephant in the room? The 2017 insider trading scandal that led to $4.6M in SEC fines and prison time for two partners (later overturned on appeal). While Flynn himself wasn't implicated and the firm has clearly moved past it, it's a reminder that even top-tier firms can have compliance blind spots.

KEY TAKEAWAYS
  • Best for: Serious biotech/pharma companies wanting operational support beyond capital
  • Watch out for: Past compliance issues, though leadership has clearly addressed them
  • Known for: Deep healthcare expertise, university partnerships, and hands-on value creation
Investment Thesis

Deerfield invests across the healthcare continuum with an emphasis on therapeutics, digital health, care delivery models, and AI-driven technologies. They deploy capital through direct investments, collaborative research agreements, and internally incubated ventures to advance healthcare and improve global health outcomes.

Stage & Sector Focus

Exclusively healthcare-focused from early stage to growth stage across therapeutics, medical devices, diagnostics, and healthcare services. With $15+ billion in assets under management and 200+ portfolio companies, they invest from seed through public markets with a strong bent toward biotech/pharma creation through university partnerships.

Notable Portfolio
BridgeBioSpringWorks TherapeuticsMelinta TherapeuticsNuvalentBicara TherapeuticsArvinasSpark TherapeuticsMyLaurel
Key Partners
James Flynn
Managing Partner & CEO

Joined in 2000, took over leadership in 2005 from founder Arnold Snider. Former top-ranked pharma analyst at Furman Selz and VP of Corporate Development at Alpharma. Has transformed Deerfield into one of the largest dedicated healthcare investment firms globally with $15+ billion AUM.

Have a specific question about Deerfield Management?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1